Assembly Biosciences Inc. Daily Stock Analysis

Daily Stock Analysis, ASMB, Assembly Biosciences Inc, priceseries

Assembly Biosciences Inc. Daily Stock Analysis
Stock Information
Open
1.48
Close
1.52
High
1.59
Low
1.44
Previous Close
1.49
Daily Price Gain
0.03
YTD High
2.45
YTD High Date
Jan 3, 2022
YTD Low
1.40
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.93
YTD Gain
-37.96%
52 Week High
5.25
52 Week High Date
Mar 15, 2021
52 Week Low
1.40
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-3.19
52 Week Gain
-67.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 12. 2017
13.79
Feb 10. 2017
19.80
20 Trading Days
43.58%
Link
LONG
Jul 28. 2017
21.78
Oct 12. 2017
34.52
53 Trading Days
58.52%
Link
LONG
Nov 16. 2017
34.95
Dec 7. 2017
42.63
14 Trading Days
21.98%
Link
LONG
Feb 13. 2018
47.92
Mar 5. 2018
56.49
13 Trading Days
17.88%
Link
LONG
Oct 15. 2019
9.30
Nov 8. 2019
15.26
18 Trading Days
64.11%
Link
LONG
Nov 22. 2019
14.10
Dec 30. 2019
20.69
24 Trading Days
46.72%
Link
LONG
Feb 3. 2020
18.36
Feb 24. 2020
20.66
14 Trading Days
12.51%
Link
LONG
Jun 15. 2020
21.28
Jun 26. 2020
22.71
9 Trading Days
6.71%
Link
Company Information
Stock Symbol
ASMB
Exchange
NasdaqCM
Company URL
http://www.assemblybio.com
Company Phone
(212) 554-4388
CEO
Derek A. Small
Headquarters
Indiana
Business Address
11711 N. MERIDIAN STREET, SUITE 310, CARMEL, IN 46032
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001426800
About

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics designed to restore health to a dysbiotic microbiome. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.

Description

Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its lead product candidate from the platform is AB-M101 that has been completed Phase Ia clinical trial to treat clostridium difficile infections. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading